{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"5.78","value":"0"},{"groupId":"OG001","lowerLimit":"0.00","upperLimit":"60.24","value":"0"},{"groupId":"OG002","lowerLimit":"0.00","upperLimit":"30.85","value":"0"},{"groupId":"OG003","lowerLimit":"0.00","upperLimit":"12.77","value":"0"},{"groupId":"OG004","lowerLimit":"0.00","upperLimit":"33.63","value":"0"},{"groupId":"OG005","lowerLimit":"0.00","upperLimit":"33.63","value":"0"},{"groupId":"OG006","lowerLimit":"0.95","upperLimit":"25.13","value":"7.7"},{"groupId":"OG007","lowerLimit":"0.21","upperLimit":"38.48","value":"8.3"},{"groupId":"OG008","lowerLimit":"0.21","upperLimit":"38.48","value":"8.3"},{"groupId":"OG009","lowerLimit":"0.00","upperLimit":"33.63","value":"0"},{"groupId":"OG010","lowerLimit":"0.09","upperLimit":"18.35","value":"3.6"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25.16","upperLimit":"50.31","value":"37.1"},{"groupId":"OG001","lowerLimit":"6.76","upperLimit":"93.24","value":"50.0"},{"groupId":"OG002","lowerLimit":"0.00","upperLimit":"30.85","value":"0"},{"groupId":"OG003","lowerLimit":"0.91","upperLimit":"24.29","value":"7.4"},{"groupId":"OG004","lowerLimit":"2.81","upperLimit":"60.01","value":"22.2"},{"groupId":"OG005","lowerLimit":"0.28","upperLimit":"48.25","value":"11.1"},{"groupId":"OG006","lowerLimit":"33.37","upperLimit":"73.41","value":"53.8"},{"groupId":"OG007","lowerLimit":"2.09","upperLimit":"48.41","value":"16.7"},{"groupId":"OG008","lowerLimit":"0.21","upperLimit":"38.48","value":"8.3"},{"groupId":"OG009","lowerLimit":"7.49","upperLimit":"70.07","value":"33.3"},{"groupId":"OG010","lowerLimit":"4.03","upperLimit":"32.67","value":"14.3"}]}],"title":"PR"},{"categories":[{"measurements":[{"comment":"N/A= VGPR data only collected in multiple myeloma cohort","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"N/A= VGPR data only collected in multiple myeloma cohort","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"N/A= VGPR data only collected in multiple myeloma cohort","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"N/A= VGPR data only collected in multiple myeloma cohort","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"N/A= VGPR data only collected in multiple myeloma cohort","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG005","lowerLimit":"0.28","upperLimit":"48.25","value":"11.1"},{"comment":"N/A= VGPR data only collected in multiple myeloma cohort","groupId":"OG006","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"N/A= VGPR data only collected in multiple myeloma cohort","groupId":"OG007","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"N/A= VGPR data only collected in multiple myeloma cohort","groupId":"OG008","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"N/A= VGPR data only collected in multiple myeloma cohort","groupId":"OG009","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"N/A= VGPR data only collected in multiple myeloma cohort","groupId":"OG010","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"VGPR"},{"categories":[{"measurements":[{"comment":"N/A= sCR data only collected in multiple myeloma cohort","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"N/A= sCR data only collected in multiple myeloma cohort","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"N/A= sCR data only collected in multiple myeloma cohort","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"N/A= sCR data only collected in multiple myeloma cohort","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"N/A= sCR data only collected in multiple myeloma cohort","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG005","lowerLimit":"0.00","upperLimit":"33.63","value":"0"},{"comment":"N/A= sCR data only collected in multiple myeloma cohort","groupId":"OG006","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"N/A= sCR data only collected in multiple myeloma cohort","groupId":"OG007","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"N/A= sCR data only collected in multiple myeloma cohort","groupId":"OG008","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"N/A= sCR data only collected in multiple myeloma cohort","groupId":"OG009","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"N/A= sCR data only collected in multiple myeloma cohort","groupId":"OG010","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"sCR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"27"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"26"},{"groupId":"OG007","value":"12"},{"groupId":"OG008","value":"12"},{"groupId":"OG009","value":"9"},{"groupId":"OG010","value":"28"}],"units":"Participants"}],"description":"ORR: percentage of participants with an objective response (OR) (CR, PR, sCR or VGPR) on 2 occasions \\>/= 4 weeks apart as assessed by the Investigator using RECIST v1.1. or IMWG criteria. RECIST v1.1: CR: disappearance of all target lesions; PR: \\>/= 30% decrease in the sum of diameters of target lesions. IMWG: CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \\</= 5% plasma cells in bone marrow; PR: \\>/= 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \\>/= 90% or to \\<200 mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or \\>/= 90% reduction in serum M-protein plus urine M-protein level \\< 100 mg per 24 hour; sCR: CR plus normal FLC ratio and no clonal cells in bone marrow.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with NSCLC were treated with vemurafenib monotherapy.","id":"OG000","title":"Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - Vemurafenib"},{"description":"Participants with ovarian cancer were treated with vemurafenib monotherapy.","id":"OG001","title":"Cohort 2: Ovarian Cancer - Vemurafenib"},{"description":"Participants with colorectal cancer were treated with vemurafenib monotherapy.","id":"OG002","title":"Cohort 3a: Colorectal Cancer - Vemurafenib"},{"description":"Participants with colorectal cancer were treated with vemurafenib and cetuximab combination therapy.","id":"OG003","title":"Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab"},{"description":"Participants with cholangiocarcinoma were treated with vemurafenib monotherapy.","id":"OG004","title":"Cohort 4: Cholangiocarcinoma - Vemurafenib"},{"description":"Participants with multiple myeloma were treated with vemurafenib monotherapy.","id":"OG005","title":"Cohort 6: Multiple Myeloma - Vemurafenib"},{"description":"Participants with Erdheim-Chester disease (ECD) or Langerhans cell histiocytosis (LCH) were treated with vemurafenib monotherapy.","id":"OG006","title":"Cohort 7a: ECD/LCH - Vemurafenib"},{"description":"Participants with anaplastic thyroid cancer were treated with vemurafenib monotherapy.","id":"OG007","title":"Cohort 7b: Anaplastic Thyroid Cancer - Vemurafenib"},{"description":"Participants with advanced stage astrocytoma were treated with vemurafenib monotherapy.","id":"OG008","title":"Cohort 7c: Advanced Stage Astrocytoma - Vemurafenib"},{"description":"Participants with early stage astrocytoma were treated with vemurafenib monotherapy.","id":"OG009","title":"Cohort 7d: Early Stage Astrocytoma - Vemurafenib"},{"description":"Participants with other BRAF V600-positive tumors were treated with vemurafenib monotherapy.","id":"OG010","title":"Cohort 7: Other BRAF V600-positive Tumors - Vemurafenib"}],"paramType":"NUMBER","populationDescription":"ITT population included all participants enrolled in the study irrespective of whether they had received study medication or not.","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years","title":"Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}